Veristat Expands its Expertise and Scale across Biopharma and Medtech

Article content material

Acquires Swiss-based multi-disciplinary consultancy SFL (Options for Life Sciences) to speed up the event of and entry to modern remedies

SOUTHBOROUGH, Mass. — Veristat, a scientific-minded international scientific analysis group (CRO), introduced at the moment the enlargement and strengthening of its service capabilities by buying SFL (Options for Life Sciences). With headquarters in Basel, Switzerland and a number of other European associates, SFL brings distinctive capabilities and a extremely credentialed workforce to help a rising variety of biotech, pharmaceutical and medtech corporations.

Article content material

Led by Founder and CEO Shayesteh Fürst-Ladani, the SFL workforce has longstanding expertise in offering strategic recommendation and operational help for all phases of product growth, with in-house experience for a broad vary of product sorts together with small molecules, biologics, drug-device mixture merchandise, medical gadgets, in vitro diagnostics (IVDs) and superior remedy medicinal merchandise (ATMPs).

The SFL workforce has in depth expertise throughout a variety of therapeutic areas, from specialised experience within the area of orphan illnesses and oncology to future healthcare options that mix medicine with synthetic intelligence (AI), gadgets and diagnostics. SFL is deeply embedded within the EU, UK and Swiss healthcare ecosystem and allows a aggressive benefit for US-based corporations in search of entry into European markets.

“With scientific advances rising our understanding of advanced therapeutic challenges, our shoppers more and more search a CRO associate with expertise in addressing the intricate challenges in program design, scientific trial conduct, and the regulatory approval and commercialization course of,” acknowledged Patrick Flanagan, Chief Govt Officer at Veristat. “Now we have been impressed with Shayesteh and your entire SFL workforce who’ve a status for delivering top quality, precision and worth. Including SFL’s gifted workforce and companies to Veristat’s providing will unlock significant potential and strengthen our potential to positively affect the scientific progress, regulatory evaluation and launch success for sufferers with difficult-to-treat illnesses and circumstances.”

With SFL, Veristat additionally expands high quality assurance and pharmacovigilance capabilities into Europe and extends its core service areas into public affairs, market entry, provide chain and healthcare compliance. Veristat and SFL share widespread and in depth competencies within the areas of regulatory affairs, strategic consulting and medical writing with complementary geographic focus. Overlaying Veristat’s world-class biometrics and scientific trial operations capabilities, the becoming a member of of the organizations creates a multi-services drive round scientific analysis and growth to efficiently meet the objectives of sponsors and shoppers with an curiosity within the European area.

“The acquisition of SFL provides EU, UK and Swiss coverage expertise within the pharmaceutical sector in addition to within the medtech area,” commented Montse Barceló Riera, M.D., Vice President, Europe for Veristat. “We at the moment are capable of additional help the well being and well-being of Europeans by championing entry to top quality medical remedies.”

Article content material

“I’m delighted to have the chance to unite two skilled and deeply dedicated groups with a ardour for high quality and daring considering,” acknowledged Shayesteh Fürst-Ladani. “We at the moment are geared up with unparalleled capabilities to ship even higher worth for sponsors and shoppers. I share Veristat’s unwavering dedication to scientific integrity, distinctive efficiency and long-lasting consumer relationships and am thrilled to be embarking on a brand new journey of development collectively.”

For the reason that Firm’s founding 27 years in the past, Veristat has collaborated with a whole lot of biopharmaceutical shoppers across the globe to organize greater than 140 advertising and marketing purposes. Veristat’s daring considering, focus, and in depth expertise supporting advanced drug growth in uncommon and ultra-rare illnesses considerably impacted the approval of 12% of the 2021 U.S. Meals and Drug Administration (FDA) novel medicine. The corporate will proceed to supply a versatile partnership engagement mannequin that delivers the best scientific experience when wanted all through your entire growth journey to keep away from undertaking delays, missed milestones or deliverable failures.

About SFL

SFL is a number one Swiss-based consultancy with associates in Austria, Germany, and the UK offering built-in options to pharma, biotech and medtech corporations for international and native actions from bench to market. SFL’s in-house experience and companies mirror key features throughout a pharma or medtech product’s life cycle: regulatory affairs, high quality assurance, pharmacovigilance, medical writing, market entry, public affairs, provide chain and healthcare compliance.

SFL helps a wide range of shoppers and sponsors starting from massive pharmaceutical corporations to rising biotechs, and main diagnostics and medical gadgets producers. SFL can act as Applicant for a Advertising Authorization Utility (MAA) and as Advertising Authorization Holder (MAH) in Switzerland, the EU and the UK, and conduct submissions to well being authorities globally together with Japan’s PMDA and Well being Canada by long-term native companions.

About Veristat

Veristat, a scientific-minded international scientific analysis group (CRO), allows sponsors to unravel the distinctive and sophisticated challenges related to accelerating therapies by scientific growth to regulatory approval. With greater than 27 years’ expertise in scientific trial planning and execution, Veristat is provided to help any growth program. Our workforce has ready almost 100 advertising and marketing purposes for approval with international regulatory authorities within the final 10 years.

Article content material

Veristat’s deal with novel drug growth has led to success when dealing with the unknowns that come up throughout sophisticated therapeutic areas, equivalent to uncommon/ultra-rare illness, superior therapies, oncology, and infectious illness trials. We apply this data base on daily basis to unravel any scientific program’s challenges, from the only to probably the most advanced. Veristat has assembled a unprecedented workforce of specialists worldwide who’ve mastered therapeutic growth intricacies, enabling sponsors to reach extending and saving lives.

View supply model on businesswire.com: https://www.businesswire.com/information/residence/20220307005044/en/

Contacts

Lauren L. Brennan, Director of Advertising
media@veristat.com

#distro